NCT07199959View on ClinicalTrials.gov

Study on the Mechanism of Acquired Resistance of Entrectinib

RecruitingOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

January 15, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 1, 2026

Conditions
ROS1 Fusion PositiveNon Small Cell Lung Cancer
Interventions
PROCEDURE

venipuncyure

venipuncture as clinical practical setting

DRUG

Entrectinib

600mg, oral, once daily

Trial Locations (1)

Unknown

RECRUITING

Fudan university shanghai cancer center, Shanghai

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

collaborator

The First Affiliated Hospital of Shanghai Jiaotong University

UNKNOWN

lead

Fudan University

OTHER